Clinical Evidence

How much medical device clinical trials cost in 2026 — per-patient costs, site fees, CRO budgets, IDE preparation, monitoring, and total budget ranges from $300K early feasibility to $20M+ pivotal studies, with cost-saving strategies for 510(k), De Novo, and PMA pathways.

How to collect, validate, and submit Patient Preference Information (PPI) for medical device regulatory submissions under FDA's March 2026 final guidance — expanded scope to 510(k), IDE, and Breakthrough Device submissions, study design methods, benefit-risk assessment integration, and alignment with EU MDR/IVDR post-market follow-up principles.

How to conduct clinical evaluation for Software as a Medical Device (SaMD) — valid clinical association, analytical validation, and clinical performance under IMDRF N41, FDA requirements, and EU MDR Article 61, including generating clinical evidence without traditional clinical trials, real-world data strategies, and navigating the January 2026 FDA withdrawal of the SaMD clinical evaluation guidance.

W.L. Gore completed its acquisition of Conformal Medical in February 2026, adding the investigational CLAAS AcuForm left atrial appendage occlusion system to its cardiovascular portfolio. Covers foam-based LAAO technology designed to conform to variable anatomies, the $1.2B LAAO device market dominated by Boston Scientific's Watchman and Abbott's Amulet, the CONFORM pivotal trial, and how a rare strategic acquisition by the privately held materials science giant reshapes competitive dynamics in structural heart.

Medtronic completed its acquisition of CathWorks for $585M in April 2026, adding the AI-powered FFRangio system for non-invasive coronary physiology assessment, and signed a definitive agreement to acquire Scientia Vascular for $550M in March 2026 for its microfabricated neurovascular guidewires and catheters. Covers how the AI-driven FFRangio system derives fractional flow reserve from routine angiograms, Scientia's nitinol microfabrication technology for stroke intervention, and Medtronic's post-MiniMed acquisition strategy focused on high-growth cardiovascular and neuroscience tuck-in deals.

CareDx agreed to acquire Naveris for up to $260M on April 28, 2026, marking its strategic expansion from transplant diagnostics into HPV-driven cancer surveillance. Covers NavDx liquid biopsy technology, TTMV DNA biomarker science, deal structure ($160M upfront + $100M milestones), CareDx's divestiture of Lab Products, and the $4.5B molecular residual disease monitoring market.

Johnson & Johnson entered a definitive agreement to acquire Atraverse Medical on April 24, 2026, adding the FDA-cleared HOTWIRE Transseptal Access System to its cardiac ablation portfolio. Covers RF-guidewire technology for left-heart access, the Atraverse founding team behind Farapulse (Boston Scientific), J&J's electrophysiology strategy including Shockwave and Varipulse, and the competitive landscape in the $10B+ cardiac rhythm management market.

Stryker completed its acquisition of Amplitude Vascular Systems on May 7, 2026, adding next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio. Covers the CO2-generated pressure wave platform, why IVL matters for calcified PAD treatment, competitive dynamics with J&J/Shockwave, regulatory pathway, and implications for the $4B+ peripheral vascular device market.

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.

How to prepare the consultation file for IVDR companion diagnostics — notified body submission to EMA or national medicinal product authorities, package contents, analytical and clinical performance evidence, drug label alignment, timing, deficiency risks, and the Team-NB V2 decision flowchart for significant changes.

How to design a PMCF survey under EU MDR that Notified Bodies accept as Level 4 clinical evidence — sample frame construction, inclusion/exclusion criteria, endpoint mapping to CER claims, acceptance criteria, statistical power, bias controls, adverse event capture, and when surveys alone are insufficient.

Practical playbook for responding to Notified Body deficiencies on SSCP documents under EU MDR — response table format, clinical benefit wording fixes, residual risk language, patient readability, CER/IFU alignment, translation consistency, and EUDAMED publication readiness.

How Good Clinical Practice applies to medical device clinical trials — navigating ISO 14155:2026 and ICH E6(R3), sponsor and investigator responsibilities, informed consent, safety reporting, and audit readiness.

Dedicated CLIA waiver playbook for IVD manufacturers — covering waived, moderate, and high complexity categories, CW submission content, flex studies, lay-user studies, the Dual 510(k) + CLIA Waiver pathway, review timelines, common deficiencies, and real-world examples.

Section-by-section CER template for EU MDR compliance — covering clinical evaluation plan, device description, literature search protocol, data appraisal tables, equivalence justification, benefit-risk analysis, PMCF linkage, evidence traceability matrix, and Notified Body-ready formatting. Free alternative to gated competitor templates.

Practical guide to using digital twins, synthetic data, and computational modeling in medical device regulatory submissions — covering FDA CM&S credibility guidance, ASME V&V 40, in silico clinical trials, synthetic control arms, model validation pitfalls, and documentation strategies.

Practical regulatory guide for home-use and self-test in vitro diagnostic devices — covering FDA pathways (OTC, prescription home use, CLIA waiver), EU IVDR self-testing requirements, human factors and lay-user usability, specimen collection errors, labeling requirements, DTC vs provider-ordered models, and post-market surveillance for consumer diagnostics.

Comprehensive regulatory and validation strategy for next-generation sequencing (NGS) in vitro diagnostic devices — covering FDA pathways (510(k), De Novo, PMA), proposed CDx reclassification, EU IVDR classification, wet lab and bioinformatics pipeline validation, variant calling, reference databases, clinical validity, cybersecurity, and post-market obligations.